BeOne Medicines has been awarded an Innovation Passport for its investigational bispecific antibody BGB‑B2033, marking a significant step in the company’s plans to advance new treatment options for ...
Qnovia has secured a worldwide exclusive licence to a new antimicrobial peptide developed at the University of Virginia, ...
Sanofi has received European Commission approval to extend the indication of MenQuadfi to infants from six weeks of age, broadening access to protection against invasive meningococcal disease caused ...
Polpharma Biologics has announced that the FDA and EMA have accepted for review the BLA and MAA for PB016, a proposed ...
CelLBxHealth has announced the publication of an independent, peer‑reviewed study demonstrating that its Parsortix platform ...
Johnson & Johnson has announced positive topline results from the phase 3 MonumenTAL‑6 study, which evaluated TECVAYLI and ...
Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...
There are currently no approved pharmacological treatments for cALD in the EU.
Lundbeck has received Fast Track designation from the U.S. FDA for Lu AH69593, its lead oral orexin 2 receptor agonist in ...
GSK has secured US FDA approval for Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1‑positive ...
First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...
Infinitopes has dosed the first patient with ITOP1, its lead investigational therapeutic cancer vaccine, marking the first ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results